Evaluation of Increased Total Bilirubin
Increased total bilirubin should be evaluated with confirmation of a true liver test abnormality and then classification by bilirubin fractionation. [1] A conjugated (direct) bilirubin predominance implies hepatocellular disease or biliary obstruction in most clinical settings. [1]
Initial Confirmation and Pattern Classification
Serum testing should be repeated to confirm the abnormal liver chemistry panel before initiating further evaluation. [1] Fractionated bilirubin (direct and indirect) should be obtained to distinguish conjugated from unconjugated hyperbilirubinemia. [1]
Laboratory Assessment for Etiology
The initial laboratory evaluation for jaundice should include the following: fractionated bilirubin, complete blood count, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, alkaline phosphatase, prothrombin time and/or international normalized ratio, albumin, and protein. [2] A complete blood count with peripheral smear should be used to assess for hemolysis and hematologic contributors to increased unconjugated bilirubin. [2]
Imaging Strategy for Suspected Cholestasis or Obstruction
Ultrasonography should be used as the first-line imaging modality because it is least invasive and least expensive for evaluating obstructive etiologies. [2] If biliary obstruction or unclear biliary anatomy remains a concern, visualization of the intrahepatic and extrahepatic biliary tree should be evaluated with magnetic resonance cholangiopancreatography or endoscopic retrograde cholangiopancreatography. [2]
Management Principles After Etiologic Stratification
Definitive management should be directed at the identified cause of the bilirubin elevation. [2] Biliary obstruction due to choledocholithiasis or malignant obstruction should be managed using biliary imaging followed by endoscopic or surgical strategies as indicated by obstruction characteristics. [2] Unconjugated hyperbilirubinemia due to impaired bilirubin conjugation should be managed conservatively when benign etiologies (for example, Gilbert syndrome) are established. [2]
Monotherapy vs Combination Therapy Considerations
Targeted therapy should be limited to the specific underlying diagnosis because empiric treatment for jaundice without etiologic confirmation is not recommended by diagnostic algorithms. [2] Further testing should precede escalation to disease-specific pharmacotherapy or procedural therapy when the cause remains unclear after initial evaluation. [2]
Initiation Thresholds for Urgent Escalation
Acute jaundice should be treated as a marker of potentially significant underlying disease requiring expedited evaluation. [2] Severe or clinically unstable presentations should prompt immediate diagnostic and therapeutic escalation for the suspected underlying etiology using the same laboratory-plus-imaging framework. [2]
Common Pitfalls to Avoid
Skin color changes consistent with jaundice should not be assumed to represent hyperbilirubinemia because pseudojaundice can occur with non-bilirubin causes such as carotenemia and spray-tanning products. [2] Incomplete characterization using total bilirubin alone should be avoided because fractionation is required to differentiate conjugated from unconjugated hyperbilirubinemia. [1] Failure to repeat abnormal results when initial testing suggests an abnormal liver chemistry panel should be avoided. [1]
Diagnostic Escalation When Initial Workup Is Non-diagnostic
Liver biopsy should be reserved for cases of jaundice where diagnosis remains unclear after history and physical examination, laboratory evaluation, and imaging. [2] Liver biopsy should be performed only when biopsy results are expected to impact treatment and prognosis. [2]